Secondary research
Scantechnology options
Understand the field
We used secondary research to understand the field and profile technical approaches that could deliver much higher viral titer.
Case Study · Technology Assessment
Raising the viral titer of bioreactors for gene therapy.
A global biotechnology company wanted to know which new technologies could lift viral titer in its bioreactors, and whether to license, buy or build them. We compared the options and helped the client set realistic expectations.
The Client
The client is a global biotechnology company looking to improve viral production in bioreactor systems for gene therapy. It engaged Prescouter through a Research Support Service project to find hard numbers on new technologies and decide whether to license or acquire a solution, or develop one in house.
The Challenge
Map the options.
Put numbers on each one.
Prescouter was asked to map the technologies that could raise virus production in bioreactors, compare them with real data, and recommend how to proceed.
-
What exists
New and upcoming technologies
Technologies that could raise virus production levels in bioreactors.
-
How they compare
Quantitative data and IP
Data and patents for each technology, used to rank them from most to least promising.
-
What to do
Strategic recommendations
How to acquire or implement the most promising technologies.
Our Approach
Testing a working hypothesis with research and experts.
Client review
Reviewan initial hypothesis
Agree the direction
An initial hypothesis was reviewed with the client team before going further.
Expert interviews
Verifywith field experts
Check with experts
We then tested the hypothesis through a series of interviews with subject matter experts.
The Outcome
Realistic gains, backed by a working model.
Prescouter built a preliminary ROI model and advised the client on the level of improvement it could reasonably expect from each approach. The client built this analysis into its business development process.
-
Returns
A preliminary ROI model
A model of the returns the client could expect from each approach.
-
Expectations
What improvement to expect
A realistic view of the titer gains each approach could deliver.
-
Strategy
License, acquire or build
Guidance on how to acquire or implement the most promising technologies.
Big claims about viral yield are easy to find. Knowing what improvement you can actually expect, and what it is worth, is what moves a decision.
Let’s Talk
Where could your process gain the most yield?
Build your bioprocess plans on a clear view of the technologies, the data, and the returns. Wherever you’re starting from, we’ll help you get there.
Or email [email protected]